Redesigned CAR-T eliminates dangerous cytokine release syndrome in lymphoma trial

Personalized CAR-T treatments for leukemia and lymphoma have offered new hope for patients with tough-to-treat disease, but the engineered cell therapies can cause a dangerous immune reaction called cytokine release syndrome (CRS). Researchers led by the University of Southern California Norris Comprehensive Cancer Center have designed a new type of CAR-T to eliminate that side effect—and they have evidence from a small human study that they’re on the right track.